Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Petitou

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
The Journal of Biological Chemistry|January 25, 1989
Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and chargeT C Wright, J J Castellot, M Petitou, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1978
Decreased microviscosity of membrane lipids in leukemic cells: two possible mechanismsM Petitou, F Tuy, C Rosenfeld, et al.
The American Journal of Pathology|December 1, 1991
Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivoL A Pukac, G M Hirsch, J C Lormeau, et al.
Annals of the New York Academy of Sciences|January 1, 1989
Heparin, heparan sulfate, smooth muscle cells, and atherosclerosisM J Karnovsky, T C Wright, J J Castellot, et al.
Biochemical and Biophysical Research Communications|April 16, 1985
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residueG Torri, B Casu, G Gatti, et al.
Journal of Thrombosis and Haemostasis : JTH|November 19, 2013
EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugsP Gueret, C Krezel, E Fuseau, et al.
The Biochemical Journal|September 15, 1986
Endothelial binding sites for heparin. Specificity and role in heparin neutralizationT Bârzu, J L Van Rijn, M Petitou, et al.
The Journal of Cell Biology|May 1, 1986
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate groupJ J Castellot, J Choay, J C Lormeau, et al.
Thrombosis Research|September 15, 1986
Heparin fractions with high and low affinities to antithrombin III are cleared at different ratesC Caranobe, M Petitou, D Dupouy, et al.
Bioorganic & Medicinal Chemistry|September 11, 1999
A synthetic heparan sulfate pentasaccharide, exclusively containing L-iduronic acid, displays higher affinity for FGF-2 than its D-glucuronic acid-containing isomersJ Kovensky, P Duchaussoy, F Bono, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
The Journal of Biological Chemistry|January 25, 1989
Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and chargeT C Wright, J J Castellot, M Petitou, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 1978
Decreased microviscosity of membrane lipids in leukemic cells: two possible mechanismsM Petitou, F Tuy, C Rosenfeld, et al.
The American Journal of Pathology|December 1, 1991
Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivoL A Pukac, G M Hirsch, J C Lormeau, et al.
Annals of the New York Academy of Sciences|January 1, 1989
Heparin, heparan sulfate, smooth muscle cells, and atherosclerosisM J Karnovsky, T C Wright, J J Castellot, et al.
Biochemical and Biophysical Research Communications|April 16, 1985
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residueG Torri, B Casu, G Gatti, et al.
Journal of Thrombosis and Haemostasis : JTH|November 19, 2013
EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugsP Gueret, C Krezel, E Fuseau, et al.
The Biochemical Journal|September 15, 1986
Endothelial binding sites for heparin. Specificity and role in heparin neutralizationT Bârzu, J L Van Rijn, M Petitou, et al.
The Journal of Cell Biology|May 1, 1986
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate groupJ J Castellot, J Choay, J C Lormeau, et al.
Thrombosis Research|September 15, 1986
Heparin fractions with high and low affinities to antithrombin III are cleared at different ratesC Caranobe, M Petitou, D Dupouy, et al.
Bioorganic & Medicinal Chemistry|September 11, 1999
A synthetic heparan sulfate pentasaccharide, exclusively containing L-iduronic acid, displays higher affinity for FGF-2 than its D-glucuronic acid-containing isomersJ Kovensky, P Duchaussoy, F Bono, et al.
Pageof 12